Infliximab  Remicade ®

Usual Diluents

NS

Standard Dilutions   [Amount of drug]  [Infusion volume]  [Infusion rate]

[Prescribed dose] [250 ml] [2 hours] Recommended conc: 0.4 to 4 mg/ml Infusions less than 2 hours are not recommended.

Stability / Miscellaneous

Stability: Use immediately.  Infusion should begin within 3 hours of preparation.  Label: Do not shake.  Reconstitute each vial with 10 ml of sterile water for injection using a syringe with a 21-gauge needle or smaller. Direct stream to sides of vial. Do not use if vacuum not present in vial. Gently swirl solution by rotating vial to dilute; do not shake. May foam upon reconstitution; allow to stand for 5 minutes. Solution is colorless to light yellow and opalescent; a few translucent particles may develop as infliximab is a protein. Do not use if opaque particles, discoloration, or other particles occur. Withdraw volume of total infliximab dose from infusion container containing 250 ml 0.9% NaCl. Slowly add total dose of infliximab for a concentration ranging from 0.4 to 4 mg/ml. Mix gently. Do not reuse or store any portion of infusion. Use an in-line, sterile, non-pyrogenic, low protein-binding filter with 1.2 micron pore size or less.     Dosing: Crohn's disease: 5 milligrams/kilogram (mg/kg) via intravenous (IV) infusion. In patients with fistulizing disease, an initial 5 milligrams/kilogram dose should be followed with additional 5 milligrams/kilogram doses at 2 and 6 weeks after the first infusion. Rheumatoid arthritis: The recommended dose is 3 milligrams/kilogram via intravenous infusion followed with additional doses of 3 milligrams/kilogram at 2 and 6 weeks after the first infusion then every 8 weeks thereafter. Infliximab should be given with methotrexate .  Supplied: 100mg vial (refrigerate)